Scientific innovation alone is rarely enough to bring an advanced therapy to patients. From early research stages to future clinical application, advanced therapy medicinal products (ATMPs) require coordination between multiple disciplines, infrastructures and regulatory frameworks.

From early research stages to future clinical application, advanced therapy medicinal products (ATMPs) require coordination between multiple disciplines, infrastructures and regulatory frameworks. In this context, European collaborative projects have become an important platform for connecting the different actors involved in translational development.

The role of European consortia in advanced therapies

European-funded consortia are designed to support projects that require collaboration between public and private entities across different countries and areas of expertise.

In the field of advanced therapies, this model is particularly relevant. Many projects originate in academic or hospital-based research environments, but progressing towards future clinical use requires additional capabilities related to manufacturing, regulation, industrial development and market access.

European consortia make it possible to integrate these different perspectives within the same project structure, bringing together:

• Research centres
• Hospitals
• Biotech companies
• Small and medium-sized companies
• Patient associations
• Regulatory or technical specialists

This collaborative framework helps create a more connected development pathway from research to potential clinical application.

Why multidisciplinary collaboration matters

One of the main advantages of international collaboration is the opportunity to combine complementary expertise and approaches.

Working with partners from different European countries allows organisations to exchange knowledge, compare methodologies and learn from different operational and regulatory environments. It also helps create broader networks that can support future stages of development.

At the same time, these collaborations require a high level of coordination. Each institution operates under its own internal structures, administrative processes and national regulations, making alignment an important part of the project itself.

For this reason, defining responsibilities, objectives and expectations from the beginning becomes essential.

The importance of the Grant Agreement

Within European projects, one of the key documents governing collaboration is the Grant Agreement.

This framework establishes the role of each partner, the project objectives, budget allocation, task distribution and the management of results and intellectual property.

Much of the long-term stability of a consortium depends on these initial negotiations. Establishing clear conditions early helps minimise future conflicts and ensures that all participants share a common understanding of how the project will operate.

Beyond research: preparing projects for future application

European projects increasingly place emphasis not only on scientific development, but also on the future impact and sustainability of the technologies being developed.

As a result, projects are expected to incorporate areas such as:

• Regulatory planning
• Dissemination and communication
• Market analysis
• Exploitation strategies
• Future commercialisation pathways

Even in relatively early-stage projects, the expectation is that research should move progressively towards practical application and eventual patient impact.

TRIANKLE: an example of translational collaboration

TRIANKLE is a European project funded under Horizon 2020 in which Gradocell participates in regulatory and ethical work packages. The project focuses on the development of personalised tendons, cartilage and ligaments using 3D bioprinting technologies.

To support this objective, the consortium combines multiple technologies and specialised partners, including biomaterials based on collagen, recombinant proteins, gelatin-based materials, 3D bioprinting systems, dissemination and exploitation specialists, patient associations and sports-related organisations.

Each partner contributes from its own area of expertise within a coordinated European framework.

Regulatory challenges in highly innovative technologies

Projects involving disruptive technologies often face an additional challenge: regulatory frameworks may still be evolving alongside the science itself.

In areas such as biofabrication or advanced tissue engineering, developers must navigate situations where regulatory expectations are not yet fully standardised. This makes early regulatory planning especially important, even during preclinical stages.

Integrating regulatory perspectives from the beginning helps development teams anticipate future requirements and structure projects more effectively over time.

Ensuring continuity beyond initial funding

One of the recurring questions in European collaborative projects is how to ensure continuity once the initial funding period comes to an end.

In projects such as TriAnkle, early stages focus on validating technologies and generating preclinical data. Future development may then require additional preclinical studies, quality system validation, regulatory progression, clinical trial preparation and new funding strategies.

Continuation can come through further European funding programmes or through industrial investment from participating partners interested in advancing the technology towards clinical application.

A long-term approach to advanced therapy development

The development of advanced therapies is a long and multidisciplinary process that depends on much more than scientific discovery alone.

European collaborative projects provide a framework that helps integrate research, regulation, industrial development and long-term strategic planning within the same ecosystem.

For highly complex technologies such as ATMPs, this coordinated approach can play an important role in supporting the transition from experimental development to future clinical use.